Department of Endocrinology and Metabolism, Ankara Güven Hospital, Ankara, Turkey.
Department of Internal Medicine, Division of Endocrinology and Metabolism, Hacettepe University School of Medicine, Ankara, Turkey.
Endocrine. 2022 Oct;78(1):42-46. doi: 10.1007/s12020-022-03130-8. Epub 2022 Jul 9.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have been reported to trigger immune side effects. Type 1 diabetes as a manifestation of autoimmune/inflammatory syndrome induced by adjuvants has been reported in a limited number of cases after vaccinations. A few type 1 diabetes cases after SARS-CoV-2 vaccination have been reported. This study aims to report type 1 diabetes cases associated with the mRNA-based SARS-CoV-2 vaccination.
We report four cases of type 1 diabetes mellitus after mRNA-based SARS-CoV-2 vaccine, BNT162b2 (Pfizer-BioNTech). In the medical history, one subject had autoimmune thyroid disease. All patients had autoantibodies against glutamate decarboxylase.
In the presented case series, type 1 diabetes developed a few weeks after BNT162b2 vaccination. After developing type 1 diabetes, the insulin dose requirements of all patients decreased rapidly, and the need for insulin therapy in three patients disappeared during follow-up. Acute deterioration of glucose regulation in a patient followed by BNT162b2 administration may be due to vaccine-induced autoimmune diabetes.
Vaccination with BNT162b2 may trigger type 1 diabetes.
据报道，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗会引发免疫副作用。在接种疫苗后，有限数量的病例报告了表现为佐剂诱发的自身免疫/炎症综合征的 1 型糖尿病。也有少数接种 SARS-CoV-2 疫苗后发生 1 型糖尿病的病例报告。本研究旨在报告与基于 mRNA 的 SARS-CoV-2 疫苗接种相关的 1 型糖尿病病例。
我们报告了 4 例接受基于 mRNA 的 SARS-CoV-2 疫苗（BNT162b2，辉瑞-生物科技）后发生 1 型糖尿病的病例。在病史中，有 1 名患者患有自身免疫性甲状腺疾病。所有患者均存在谷氨酸脱羧酶自身抗体。
在本病例系列中，BNT162b2 接种后数周内发生 1 型糖尿病。发生 1 型糖尿病后，所有患者的胰岛素剂量需求迅速下降，3 名患者在随访期间胰岛素治疗需求消失。一名患者在接受 BNT162b2 治疗后出现血糖调节急剧恶化，可能是疫苗诱导的自身免疫性糖尿病所致。
接种 BNT162b2 可能会引发 1 型糖尿病。
